Company / Operating Cash Flow per Share
Viridian Therapeutics, Inc.\DE Operating Cash Flow per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.87
FY2024
5-year range
-$4.58 / -$2.87
FY2020-FY2024
Trend
+30.3%
vs FY2023
Sector context
#168 of 212
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's operating cash flow per share of $-2.87 is lower than 79% of companies in the Health Care sector (FY2024). Operating Cash Flow per Share has fluctuated over the past 9 years, ranging from $-33.78 in FY2017 to $-0.91 in FY2018.
Based on SEC 10-K filings.
-2.87 in FY2024.
Remained stable around $-2.87 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
+80.5% above sector average
Key checks
Key Insights
- In FY2024, operating cash flow per share increased 30.3% year-over-year.
- Ranks #168 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2018.
- Lowest operating cash flow per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -$2.87 | +30.3% |
| FY2023 | -$4.12 | -40.7% |
| FY2022 | -$2.92 | +36.1% |
| FY2021 | -$4.58 | +45.3% |
| FY2020 | -$8.37 | +51.5% |
| FY2019 | -$17.26 | -1803.1% |
| FY2018 | -$0.91 | +97.3% |
| FY2017 | -$33.78 | -62.3% |
| FY2016 | -$20.81 | -1041.2% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026